(Worthy News) – A new drug being developed in Israel could be the answer to treating the main cause of Type 2 Diabetes, insulin resistance.
According to Concenter BioPharma co-founder and CSO Prof. Mottie (Mordechai) Chevion, “the unique property” of the drug, called Zygosid-50 “is that it cancels out insulin resistance.
💡 Did you know? One of the best ways you can support
Worthy News is by simply
leaving a comment and sharing this article.
📢 Social media algorithms push content further when there’s more engagement —
so every 👍 like, 💬 comment, and 🔄 share helps more people discover the truth. 🙌
Fair Use Notice:This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.
(Worthy News) – A new drug being developed in Israel could be the answer to treating the main cause of Type 2 Diabetes, insulin resistance.